Last reviewed · How we verify
Aminarson (carbarsone)
Aminarson (generic name: carbarsone) is a carbarsone drug. It is currently in unknown development for Acute amebiasis.
Aminarson works by inhibiting the growth of the parasite Entamoeba histolytica, ultimately leading to its death.
Aminarson, also known as carbarsone, is a small molecule drug in the carbarsone class. It is used to treat acute amebiasis, a condition caused by the parasite Entamoeba histolytica. The commercial status of Aminarson is unclear, but it is likely to be a generic or off-patent medication. Aminarson's mechanism of action involves inhibiting the growth of the parasite, ultimately leading to its death. Further information on its development, approval, and safety considerations is needed.
At a glance
| Generic name | carbarsone |
|---|---|
| Drug class | carbarsone |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine your body is a garden, and the parasite is a weed that's taking over. Aminarson is like a weed killer that stops the weed from growing and eventually kills it, allowing your body's natural defenses to take over and heal.
Approved indications
- Acute amebiasis
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aminarson CI brief — competitive landscape report
- Aminarson updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Aminarson
What is Aminarson?
How does Aminarson work?
What is Aminarson used for?
What is the generic name of Aminarson?
What drug class is Aminarson in?
What development phase is Aminarson in?
Related
- Drug class: All carbarsone drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Acute amebiasis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing